TRVI vs. CRNX, KYMR, RARE, TLX, NAMS, VKTX, XENE, AMRX, SRRK, and IMVT
Should you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Crinetics Pharmaceuticals (CRNX), Kymera Therapeutics (KYMR), Ultragenyx Pharmaceutical (RARE), Telix Pharmaceuticals (TLX), NewAmsterdam Pharma (NAMS), Viking Therapeutics (VKTX), Xenon Pharmaceuticals (XENE), AMNEAL PHARMACEUTICALS (AMRX), Scholar Rock (SRRK), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry.
Trevi Therapeutics vs. Its Competitors
Crinetics Pharmaceuticals (NASDAQ:CRNX) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.
Crinetics Pharmaceuticals has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.
Crinetics Pharmaceuticals' return on equity of -32.28% beat Trevi Therapeutics' return on equity.
Trevi Therapeutics has lower revenue, but higher earnings than Crinetics Pharmaceuticals. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Crinetics Pharmaceuticals currently has a consensus price target of $65.33, suggesting a potential upside of 93.47%. Trevi Therapeutics has a consensus price target of $21.75, suggesting a potential upside of 169.85%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Trevi Therapeutics is more favorable than Crinetics Pharmaceuticals.
98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 6.0% of Crinetics Pharmaceuticals shares are owned by company insiders. Comparatively, 18.3% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Trevi Therapeutics had 12 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 19 mentions for Trevi Therapeutics and 7 mentions for Crinetics Pharmaceuticals. Trevi Therapeutics' average media sentiment score of 1.39 beat Crinetics Pharmaceuticals' score of 1.03 indicating that Trevi Therapeutics is being referred to more favorably in the news media.
Summary
Trevi Therapeutics beats Crinetics Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
Get Trevi Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Trevi Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TRVI) was last updated on 9/16/2025 by MarketBeat.com Staff
